How long does Wegovy take to work? Understanding weight loss time on semaglutide

Wegovy's average weight loss in the STEP 1 trial was around 15% of body weight over 68 weeks, at the 2.4mg maintenance dose.
The dose schedule moves slowly by design (from 0.25mg up through several steps to 2.4mg (or up to 7.2mg with the newer higher-dose pen)) to keep side effects manageable.
Early weeks on the lowest dose are about tolerance, not maximum effect; noticeable appetite changes often appear once the dose reaches a therapeutic level.
Progress is not linear: weight loss may slow, plateau or vary week to week, particularly during dose transitions.

Most people using Wegovy notice the first changes within the initial two to four weeks of starting treatment, though meaningful weight loss typically builds over several months. In the STEP 1 clinical trial, participants lost an average of around 15% of their body weight over 68 weeks — not 68 days. That gap between expectation and reality is worth sitting with before you start. Wegovy (semaglutide) is a prescription-only medicine, and how quickly it works depends on your dose, your starting point, and the lifestyle changes you make alongside it. A GLP-1 receptor agonist like semaglutide works by slowing gastric emptying and reducing appetite signals — changes that compound gradually, not overnight.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence and real-world experience tell us about Wegovy's weight loss timeline

When do most people start to see appetite and weight changes?

The first dose of Wegovy is 0.25mg, a starting point chosen specifically to let your body adjust, rather than to produce immediate weight loss. At this stage, some people notice a slight reduction in hunger within the first week or two; others feel very little different at all. That's not a sign it isn't working. Semaglutide acts on GLP-1 receptors in the gut and brain, and those effects become more pronounced as the dose rises through its titration steps.

By weeks four to eight, once the dose has increased, most people find their appetite is noticeably lower and portion sizes naturally shrink. This is when the scales tend to start moving more consistently. A question our prescribers hear often is "why am I not losing weight yet?", and the honest answer is usually that the dose is still climbing. Expecting the starter dose to do the work of the maintenance dose is the single most common misunderstanding about this treatment.

You can read a more detailed breakdown of what to expect month by month on our Wegovy weight loss timeline page.

How much weight can you expect to lose, and over what period?

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Participants on 2.4mg semaglutide lost an average of around 15% of body weight compared with roughly 2.4% in the placebo group. At the newer 7.2mg dose, trials reported average losses of around 20.7% over 72 weeks.

Those are trial averages, which means individual results ranged widely on either side. Factors that influence your own trajectory include starting weight, diet quality, activity levels, any medications you take, and how well you tolerate each dose increase. If you're wondering how long your own journey might realistically take, our page on the Wegovy weight loss time frame sets out what the evidence suggests at each stage of treatment.

One thing the data is consistent on: the majority of weight loss happens in the first year, with results slowing as the body reaches a new equilibrium. Continuing treatment and lifestyle changes is what maintains that lower weight. For a broader look at how semaglutide produces weight loss, including the mechanism behind appetite reduction, that page goes into more depth.

Does timing (day of the week, or time of day) affect how well it works?

Wegovy is a once-weekly injection. The day you choose doesn't change its effectiveness, but consistency matters: injecting on the same day each week keeps semaglutide levels steady in your bloodstream, which smooths out both appetite suppression and side effects.

Time of day is flexible (morning, evening or any other point works) though some people find injecting in the evening helps them sleep through the first wave of nausea after a dose increase. If you want to think through timing more carefully, our page on the best time of day to take semaglutide covers the practical considerations in detail.

What does affect results is adherence: skipping doses, or not titrating on schedule, interrupts the steady-state concentration that makes the medicine work. Always follow your prescriber's instructions and the patient information leaflet for missed doses, never adjust your own schedule.

What can slow progress, and when is it worth talking to a clinician?

Plateaus are normal and well-documented. Weight loss often slows around months three to four, and again during dose transitions, as the body adapts. This isn't failure; it's physiology. Protein intake, strength exercise and adequate hydration all support continued progress during flat periods, as NHS guidance on semaglutide notes alongside general dietary advice.

If you've been on a stable maintenance dose for six months and lost less than 5% of your starting weight, NICE's guidance on semaglutide recommends reviewing whether to continue. That's a clinical conversation, not a conclusion you should reach on your own. Side effects, particularly gastrointestinal symptoms, can also affect appetite and food intake in ways that complicate the picture in early weeks. If you're struggling with side effects or feel something isn't right, contact your prescribing team promptly.

You can find an overview of the full range of how Wegovy supports weight loss, including eligibility and what to expect from treatment, on our main Wegovy page. If you're ready to talk through your own situation with a clinician, a free consultation with our prescribers is the place to start, every assessment is read by a GPhC-registered Independent Prescriber, not automated software.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions